Skip to main content
Log in

Adjuvante Chemotherapie des Mammacarcinoms: Anhaltende Kontroverse

Adjuvant chemotherapy of breast cancer: Still a controversial matter

  • Editorial
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Autor ungenannt (1983) „Brustkrebs operiert: zusätzliche Chemotherapie wertlos, belastend“. Medical Tribune, S. 48, Nr. 22, 3.6.1983

  2. Bonadonna G, et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancer. New Engl J Med 294:405–410

    Google Scholar 

  3. Fisher B, et al. (1975) L-PAM in the Management of Primary Breast Cancer. New Engl J Med 292:117–122

    Google Scholar 

  4. Fisher B, et al. (1983) Influence of Tumor Estrogen and Progesterone Receptor Levels and the Response to Tamoxifen and Chemotherapy in Primary Breast Cancer. J Clin Oncol 1

  5. Sauter Ch (1983) Hat die heutige adjuvante zytostatische Therapie bei radikal operierten Mammacarcinompatientinnen versagt? Schweiz Med Wochenschr 113:414–417

    Google Scholar 

  6. Staquet M (Ed) (1972) The Design of Clinical Trials in Cancer Therapy. EORTC Publication, Brussels

    Google Scholar 

  7. Vorherr H (1983) Adjuvant Chemotherapy of Breast Cancer: Hope-Reality-Hazard. Klin Wochenschr 62:149–161

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagel, G.A. Adjuvante Chemotherapie des Mammacarcinoms: Anhaltende Kontroverse. Klin Wochenschr 62, 145–148 (1984). https://doi.org/10.1007/BF01731636

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01731636

Navigation